Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
NewAmsterdam Pharma Company (NAMS)
NASDAQ:NAMS
RESEARCH TOOLSreports
Holding NAMS?
Track your performance easily
NAMS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.63 - $26.35
Previous Close$16.4
Volume274.12K
Average Volume (3M)340.98K
Market Cap
$1.46B
Enterprise Value$1.03B
Total Cash (Recent Filing)$430.71M
Total Debt (Recent Filing)$562.00K
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Nov 11, 2024EPS Estimate
-$0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding90,015,357
10 Day Avg. Volume347,281
30 Day Avg. Volume340,979
Standard Deviation0.22
R-Squared0.00062
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)3.40
Price to Sales (P/S)357.63
Price to Cash Flow (P/CF)-6.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue451.12
Enterprise Value/Gross Profit72.97
Enterprise Value/Ebitda-25.09
Forecast
1Y Price Target
$37.67Price Target Upside129.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
NewAmsterdam Pharma Company News
Bulls Say, Bears Say
Bulls Say
EfficacyObicetrapib treatment led to 77% of patients reaching the goal LDL-C reduction level of <100mg/dL compared to placebo of 40%.
Market PotentialIf successful, obi is expected to generate blockbuster sales by addressing unmet needs in the ~30MM patients unable to meet LDL-C targets with current therapies.
Safety ProfileObicetrapib demonstrated significant improvements in non-HDL-C, Lp(a), ApoB, and HDL-C, along with an excellent safety profile comparable to placebo.
Bears Say
Clinical TrialsIf obicetrapib shows much lower efficacy in both Ph.3 trials and severe unexpected safety signals emerge, this could yield 60-80% downside in the stock.
Drug EfficacyIt's possible the LDL reduction for '0780 in the ongoing Phase IIB for patients on a stable dose of moderate / high intensity statins may get slightly lower efficacy or <50% LDL reduction.
EarningsIntraday volatility in NAMS stock seems to track with the fact that obi’s ~36% mean LDL-C reduction could be slightly below some investors’ expectations.
---
Ownership Overview
8.50% Insiders
1.16% Mutual Funds
74.98% Other Institutional Investors
15.36% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NAMS FAQ
What was NewAmsterdam Pharma Company’s price range in the past 12 months?
NewAmsterdam Pharma Company lowest stock price was $5.63 and its highest was $26.35 in the past 12 months.
What is NewAmsterdam Pharma Company’s market cap?
Currently, no data Available
When is NewAmsterdam Pharma Company’s upcoming earnings report date?
NewAmsterdam Pharma Company’s upcoming earnings report date is Nov 11, 2024 which is in 64 days.
How were NewAmsterdam Pharma Company’s earnings last quarter?
NewAmsterdam Pharma Company released its earnings results on Aug 07, 2024. The company reported -$0.41 earnings per share for the quarter, beating the consensus estimate of -$0.577 by $0.167.
Is NewAmsterdam Pharma Company overvalued?
According to Wall Street analysts NewAmsterdam Pharma Company’s price is currently Undervalued.
Does NewAmsterdam Pharma Company pay dividends?
NewAmsterdam Pharma Company does not currently pay dividends.
What is NewAmsterdam Pharma Company’s EPS estimate?
NewAmsterdam Pharma Company’s EPS estimate is -$0.5.
How many shares outstanding does NewAmsterdam Pharma Company have?
NewAmsterdam Pharma Company has 90,015,360 shares outstanding.
What happened to NewAmsterdam Pharma Company’s price movement after its last earnings report?
NewAmsterdam Pharma Company reported an EPS of -$0.41 in its last earnings report, beating expectations of -$0.577. Following the earnings report the stock price went down -3.512%.
Which hedge fund is a major shareholder of NewAmsterdam Pharma Company?
Among the largest hedge funds holding NewAmsterdam Pharma Company’s share is RA Capital Management. It holds NewAmsterdam Pharma Company’s shares valued at 155M.
---
NewAmsterdam Pharma Company Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.67 (129.70% Upside)
$37.67 (129.70% Upside)
Blogger Sentiment
Bullish
NAMS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 659.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $167.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 14.8%
Last 30 Days ▲ 14.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Company Description
NewAmsterdam Pharma Company
Frazier Lifesciences Acquisition Corp is a blank check company.
---
NAMS Stock 12 Month Forecast
Average Price Target
$37.67
▲(129.70% Upside)
Technical Analysis
ADC Therapeutics
―
Actinium Pharmaceuticals
―
Bioxcel Therapeutics
―
EyePoint Pharmaceuticals
―
Best Analysts Covering NAMS
1 Year
1 Year Success Rate
4/7 ratings generated profit
1 Year Average Return
+19.66%
reiterated a buy rating last month
Copying Dennis Ding's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +19.66% per trade.
---